ReviewCureus2025
Revolutionizing Allergy Care: Sublingual Immunotherapy for House Dust Mite Allergy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
House dust mite (HDM) allergies affect a significant portion of the global population. A considerable number of people in India suffer from allergic rhinitis (AR), and many individuals with AR are affected by HDM allergies. The management of allergic conditions, such as AR and allergic asthma (AA), has predominantly depended on drugs providing symptomatic relief and avoidance measures. These approaches do not include disease-modifying drugs and have limitations, including incomplete relief, slow onset of action, lack or drop-off in efficacy with continued use, and frequent exacerbations. With multiple species of HDM in India and high rates of sensitization among patients with nasobronchial allergy, symptomatic management is inadequate. Allergen immunotherapy (AIT), including sublingual immunotherapy (SLIT), represents the only disease-modifying treatment for allergic conditions. Unlike subcutaneous immunotherapy (SCIT), SLIT has the advantages of being non-invasive, allowing at-home administration, and having a lower potential for anaphylactic reactions. This review highlights the need for SLIT and explores the mechanism and clinical benefits of this novel immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.